Welcome to our dedicated page for USANA HEALTH SCIENCES SEC filings (Ticker: USNA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
USANA Health Sciences, Inc. filings document financial results, management commentary and Regulation FD disclosures for a health and wellness products company. Form 8-K reports cover quarterly and annual results, preliminary sales information, guidance, exhibits and conference-call materials tied to the company’s operating updates.
Proxy and governance filings address director elections, board matters, executive compensation, equity awards and pay-versus-performance disclosure. Other material-event reports document leadership changes, transition agreements and compensatory arrangements, providing formal records of governance and management structure for USANA Health Sciences.
USANA Health Sciences (USNA) disclosed an insider transaction by a director on 10/23/2025. The filing reports the acquisition of 1,057 shares of common stock via the settlement of restricted stock units (Transaction Code M). Following the transaction, the reporting person directly owns 6,315 common shares and holds 2,115 restricted stock units.
The RSUs vest in four equal installments of 25% on July 24, 2025, October 23, 2025, January 22, 2026, and April 23, 2026. The RSU settlement carried a stated price of $0 for the underlying common shares, consistent with equity award vesting mechanics.
USANA Health Sciences (USNA) disclosed insider activity dated 10/23/2025. A director acquired 1,057 shares of common stock through the conversion of restricted stock units (code M) and disposed of 476 shares (code F) at $20.63.
After the transactions, the director beneficially owned 5,918 common shares directly and held 2,115 restricted stock units. These RSUs vest 25% on July 24, 2025, October 23, 2025, January 22, 2026, and April 23, 2026.
USANA Health Sciences furnished an update on investor communications. The company announced a press release with financial results for the third quarter ended September 27, 2025, and said it will post a “Management Commentary” on its website. Executives will host a conference call with brief remarks followed by Q&A, with webcast and telephone access details provided.
The press release and Management Commentary are included as Exhibits 99.1 and 99.2 and are furnished, not filed. These materials will be available on www.usana.com.
USANA Health Sciences, Inc. filed a current report to let investors know it has released a press release with preliminary financial results for its third quarter ended September 27, 2025. The company is furnishing this information under the sections covering results of operations and Regulation FD, and it attaches the press release as Exhibit 99.1. The disclosure is classified as “furnished” rather than “filed,” which limits its use for certain legal purposes but still makes the preliminary quarterly results publicly available.
Dimensional Fund Advisors LP reports holding 915,049 shares of USANA Health Sciences Inc common stock, representing 5.0% of the class. The filing states that the reported shares are owned by investment funds advised or sub‑advised by Dimensional, which disclaims beneficial ownership and says the holdings are managed in the ordinary course of business and not for the purpose of changing or influencing control. Of the reported shares, Dimensional asserts sole voting power over 887,817 shares and sole dispositive power over 915,049 shares; no shared voting or dispositive power is reported.
The statement clarifies these holdings arise from Dimensional’s advisory roles to registered investment companies, commingled funds, group trusts and separate accounts and that no single Fund listed is known to hold more than 5% of the class. The filing includes the required certification by Dimensional’s compliance officer.
Myron W. Wentz, a director and >10% owner of USANA Health Sciences (USNA), reported a sale of 145,000 shares of Common Stock. After the reported disposition, the filing shows beneficial ownership of 7,408,345 shares held indirectly through Gull Global Limited, an entity Dr. Wentz indirectly owns and controls. The filing also explains Gull Global Limited is owned 50% by Viron Company Limited and 50% by Myogen Limited, each ultimately controlled by Dr. Wentz. The disclosure is limited to the change in share count and the ownership chain; no option or derivative transactions are reported.
USANA Health Sciences (USNA) filer submitted a Form 144 proposing the sale of 5,169 common shares through Morgan Stanley Smith Barney on the NYSE. The shares have an aggregate market value of $165,408 and the issuer reports 18,271,836 shares outstanding, making the sale a small fraction of total shares. The shares were acquired as restricted stock in early February 2025 (944 on 02/07/2025, 2,805 on 02/08/2025 and 1,420 on 02/06/2025) and the approximate sale date is listed as 08/28/2025. The filing includes the standard representation that the seller is not aware of undisclosed material adverse information.
Gilbert A. Fuller, a director of USANA Health Sciences Inc (USNA), reported a sale of 1,058 shares of common stock on 08/07/2025 at approximately $29.1014 per share. The Form 4 lists the transaction as a sale and shows 0 shares beneficially owned by Fuller following the reported transaction, with ownership held directly. The filing discloses the required Section 16 details for the transaction.
USANA Health Sciences, Inc. (USNA) — Quarterly report (10-Q) for period ended June 28, 2025.
Key financials: Net sales were $235.8M for Q2 2025, up 10.8% y/y; six‑month net sales were $485.4M. Net earnings attributable to USANA were $9.7M for Q2 (Q2 2024: $10.4M) and $19.1M for six months (prior: $27.0M). Diluted EPS was $0.52 for the quarter and $1.01 for six months.
Material events and balance sheet highlights: the company completed a controlling acquisition of Hiya on December 23, 2024 for a final purchase price of $206,074, recognizing $127.3M of goodwill and $124.2M of intangibles (acquired). Cash and cash equivalents were $151.3M as of June 28, 2025 ($154.1M total cash, cash equivalents and restricted cash). Inventories increased to $83.3M. During the six months the company repurchased and retired 927 shares for $27.7M. A redeemable noncontrolling interest in Hiya totaled $54.5M. The Credit Facility provides up to $75.0M revolver capacity; outstanding balance was $0 at June 28, 2025.
USANA Health Sciences (USNA) Form 4: Chief Sales Officer David Mulham disclosed a direct sale of company stock.
- Transaction date: 30 Jul 2025
- Shares sold: 3,515 common shares
- Sale price: $30.26 per share (approx. $106 k total proceeds)
- Shares owned after sale: 9,260 (direct)
No derivative securities were reported. The filing was signed on 31 Jul 2025.